
    
      The FARP randomized control study will compare focal ablation of prostate using High
      Intensity Focused Ultrasound (HIFU) applied by FocalOne® or TULSA® device versus Radical
      Prostatectomy (RP) in patients with unilateral, intermediate risk prostate cancer.
    
  